Benjamin J. Dugan

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

Kristine L. Stump, Lily Lu, Paweł Dobrzański et al. · Arthritis Research & Therapy · 2011 · 76 citations · Full text

Medicine, Immunology, Pharmacology +17

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Lily Lu, Kristine L. Stump, Nate H. Wallace et al. · The Journal of Immunology · 2011 · 75 citations · Full text

Medicine, Immunology, Pharmacology +16

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779

Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models

Eugen F. Mesaros, Jason P. Burke, Jonathan D. Parrish et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 34 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Structure–Activity Relationships and Discovery of (<i>S</i>)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6<i>H</i>-pyrido[1,2-<i>h</i>][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer

Dimitar Gotchev, Bruce D. Dorsey, Duyan Nguyen et al. · Journal of Medicinal Chemistry · 2024 · 13 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +17